[ Pobierz całość w formacie PDF ]

cells expressing high levels of cDNA-derived cytochrome 54. Doppenschmitt S, Spahn-Langguth H, Regardh CG, Lang-
P4503A4. Pharm Res 13:1635 1641. guth P. 1999. Role of P-glycoprotein-mediated secretion in
37. Zhou L, Yang L, Tilton S, Wang J. 2007. Development of a high absorptive drug permeability: An approach using passive
throughput equilibrium solubility assay using miniaturized membrane permeability and affinity to P-glycoprotein.
shake-flask method in early drug discovery. J Pharm Sci 96: J Pharm Sci 88:1067 1072.
3052 3071. 55. Hochman JH, Yamazaki M, Ohe T, Lin JH. 2002. Evaluation
38. Aungst BJ, Nguyen NH, Bulgarelli JP, Oates-Lenz K. 2000. of drug interactions with P-glycoprotein in drug discovery: In
The influence of donor and reservoir additives on Caco-2 vitro assessment of the potential for drug drug interactions
permeability and secretory transport of HIV protease inhibi- with P-glycoprotein. Curr Drug Metab 3:257 273.
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 7, JULY 2010
3264 SKOLNIK ET AL.
56. Gleeson MP. 2008. Generation of a set of simple, interpretable 73. Yamashita S, Hattori E, Shimada A, Endoh Y, Yamazaki Y,
ADMET rules of thumb. J Med Chem 51:817 834. Kataoka M, Sakane T, Sezaki H. 2002. New methods to
57. Artursson P, Ungell AL, Lofroth JE. 1993. Selective paracel- evaluate intestinal drug absorption mediated by oligopeptide
lular permeability in two models of intestinal absorption: transporter from in vitro study using Caco-2 cells. Drug Metab
Cultured monolayers of human intestinal epithelial cells Pharmacokinet 17:408 415.
and rat intestinal segments. Pharm Res 10:1123 1129. 74. Luckner P, Brandsch M. 2005. Interaction of 31 beta-lactam
58. Tavelin S, Taipalensuu J, Hallbook F, Vellonen KS, Moore V, antibiotics with the Hþ/peptide symporter PEPT2: Analysis of
Artursson P. 2003. An improved cell culture model based on 2/ affinity constants and comparison with PEPT1. Eur J Pharm
4/A1 cell monolayers for studies of intestinal drug transport: Biopharm 59:17 24.
Characterization of transport routes. Pharm Res 20:373 381. 75. Varma MV, Sateesh K, Panchagnula R. 2005. Functional role
59. Nagahara N, Tavelin S, Artursson P. 2004. Contribution of the of P-glycoprotein in limiting intestinal absorption of drugs:
paracellular route to the pH-dependent epithelial permeabil- Contribution of passive permeability to P-glycoprotein
ity to cationic drugs. J Pharm Sci 93:2972 2984. mediated efflux transport. Mol Pharm 2:12 21.
60. Saitoh R, Sugano K, Takata N, Tachibana T, Higashida A, 76. Stenberg P, Norinder U, Luthman K, Artursson P. 2001.
Nabuchi Y, Aso Y. 2004. Correction of permeability with pore Experimental and computational screening models for the
radius of tight junctions in Caco-2 monolayers improves the prediction of intestinal drug absorption. J Med Chem
prediction of the dose fraction of hydrophilic drugs absorbed 44:1927 1937.
by humans. Pharm Res 21:749 755. 77. Da VG, Zerrouk N, Richard I, Frendo JL, Zhiri A, Li-Khuan R,
61. Fine KD, Santa Ana CA, Porter JL, Fordtran JS. 1995. Effect Tricottet V, Provot G, Chaumeil JC, Arnaud P. 2004. Short
of changing intestinal flow rate on a measurement of intest- term Caco-2/TC7 cell culture: Comparison between conven-
inal permeability. Gastroenterology 108:983 989. tional 21-d and a commercially available 3-d system. Biol
62. Tanaka Y, Taki Y, Sakane T, Nadai T, Sezaki H, Yamashita S. Pharm Bull 27:1986 1992.
1995. Characterization of drug transport through tight-junc- 78. Bolger MB, Agoram B, Fraczkiewicz R, Steere B. 2003. Simu-
tional pathway in Caco-2 monolayer: Comparison with iso- lation of absorption, metabolism, and bioavailability. In: van
lated rat jejunum and colon. Pharm Res 12:523 528. de Waterbeemd H, Lennernas H, Artursson P, editors. Drug
63. Chiou WL, Barve A. 1998. Linear correlation of the fraction of bioavailability, methods and principles in medicinal chemis-
oral dose absorbed of 64 drugs between humans and rats. try series, 18th edition. Weinheim: Wiley-VCH Verlag GmbH
Pharm Res 15:1792 1795. & Co. pp 420 443.
64. Lau YY, Krishna G, Yumibe NP, Grotz DE, Sapidou E, Norton 79. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. 2001.
L, Chu I, Chen C, Soares AD, Lin CC. 2002. The use of in vitro Interaction of omeprazole, lansoprazole and pantoprazole
metabolic stability for rapid selection of compounds in early with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol
discovery based on their expected hepatic extraction ratios. 364:551 557.
Pharm Res 19:1606 1610. 80. Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K,
65. Pollack GM, Brouwer KL, Demby KB, Jones JA. 1990. Deter- Tsuruo T. 2003. Reversal of breast cancer resistance pro-
mination of hepatic blood flow in the rat using sequential tein-mediated drug resistance by estrogen antagonists and
infusions of indocyanine green or galactose. Drug Metab Dis- agonists. Mol Cancer Ther 2:105 112.
pos 18:197 202. 81. Benet LZ, Cummins CL, Wu CY. 2004. Unmasking the
66. www.tp-search.jp [accessed January to March 2007]. dynamic interplay between efflux transporters and metabolic [ Pobierz całość w formacie PDF ]